冠状动脉微血管内皮功能紊乱的药物治疗进展  

Progress in Drug Therapy of Coronary Microvascular Endothelial Dysfunction

作　　者：张梦奇 薛晋荣 巩杨超 姜馨[2] 

机构地区：[1]西安医学院,陕西 西安 [2]陕西省人民医院心血管内科,陕西 西安

出　　处：《临床医学进展》2022年第9期8130-8138,共9页Advances in Clinical Medicine

摘　　要：冠状动脉微血管疾病(CMVD)在心绞痛发生中的作用近年来受到了越来越多的关注,研究表明CMVD也是心血管不良事件的高危因素。然而,CMVD病因复杂、症状不典型、诊断困难,CMVD患者常常不能被及时诊断及妥善治疗。目前已知冠状动脉微血管内皮细胞(CMEC)功能异常是CMVD重要发病机制之一,能够改善冠状动脉微血管内皮功能紊乱的药物可能通过干预CMVD发病机制,为CMVD患者的治疗带来希望。本文对CMEC功能有改善的药物及其作用机制进行综述,为CMVD患者药物治疗提供理论及实践依据。The role of coronary microvascular disease (CMVD) in the occurrence of angina pectoris has at-tracted more and more attention in recent years. Studies have shown that CMVD is also a risk factor for major adverse cardiovascular events. However, the etiology of CMVD is complex, the symptoms are atypical, and the diagnosis is difficult. Patients with CMVD are often not timely diagnosed and properly treated. At present, it is known that the dysfunction of coronary microvascular endothelial cells (CMEC) is one of the important pathogenesis of CMVD. Drugs that can improve the dysfunction of coronary microvascular endothelial cells may interfere with the pathogenesis of CMVD and bring hope for the treatment of CMVD patients. In this paper, the drugs with improved CMEC function and their mechanisms were reviewed to provide theoretical and practical basis for drug treatment of CMVD patients.

关 键 词：冠脉微血管 内皮细胞 他汀类药物 降压药物 降糖药物 

分 类 号：R541.4[医药卫生—心血管疾病]